Editas Medicine, Inc. (NASDAQ:EDIT) Receives $5.40 Average Target Price from Brokerages

Posted by on Jul 29th, 2026

Editas Medicine, Inc. (NASDAQ:EDIT – Get Free Report) has earned an average recommendation of “Moderate Buy” from the seven research firms that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $5.40.

EDIT has been the topic of a number of recent research reports. Wall Street Zen downgraded shares of Editas Medicine from a “hold” rating to a “sell” rating in a research note on Sunday, May 10th. TD Cowen restated a “buy” rating on shares of Editas Medicine in a report on Wednesday, May 27th. Chardan Capital upped their target price on shares of Editas Medicine from $3.50 to $4.00 and gave the company a “buy” rating in a research report on Tuesday, May 5th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Editas Medicine in a report on Friday, July 17th.

Get Our Latest Report on Editas Medicine

Insiders Place Their Bets

In other Editas Medicine news, CEO Gilmore Neil O’neill sold 15,380 shares of the company’s stock in a transaction that occurred on Wednesday, June 3rd. The stock was sold at an average price of $2.70, for a total transaction of $41,526.00. Following the sale, the chief executive officer directly owned 248,313 shares in the company, valued at $670,445.10. This represents a 5.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 16,575 shares of company stock worth $44,752 over the last quarter. Insiders own 3.10% of the company’s stock.

Hedge Funds Weigh In On Editas Medicine

Several large investors have recently modified their holdings of the stock. Price T Rowe Associates Inc. MD raised its holdings in Editas Medicine by 7.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 92,397 shares of the company’s stock valued at $190,000 after buying an additional 6,177 shares during the period. BNP Paribas Financial Markets boosted its stake in Editas Medicine by 33.3% during the third quarter. BNP Paribas Financial Markets now owns 27,168 shares of the company’s stock worth $94,000 after buying an additional 6,787 shares during the period. Victory Capital Management Inc. purchased a new position in Editas Medicine during the third quarter worth $36,000. Captrust Financial Advisors bought a new position in Editas Medicine during the second quarter valued at $26,000. Finally, Sei Investments Co. bought a new position in Editas Medicine during the third quarter valued at $46,000. Institutional investors own 71.90% of the company’s stock.

Editas Medicine Stock Down 2.2%

Shares of EDIT stock opened at $2.62 on Wednesday. The company’s fifty day simple moving average is $2.95 and its two-hundred day simple moving average is $2.61. Editas Medicine has a 52 week low of $1.66 and a 52 week high of $4.54. The stock has a market cap of $256.52 million, a P/E ratio of -2.13 and a beta of 2.10.

Editas Medicine (NASDAQ:EDIT – Get Free Report) last posted its earnings results on Tuesday, May 5th. The company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.04. Editas Medicine had a negative return on equity of 677.39% and a negative net margin of 281.59%.The firm had revenue of $2.83 million during the quarter, compared to the consensus estimate of $6.37 million. On average, analysts anticipate that Editas Medicine will post -1.03 EPS for the current fiscal year.

Editas Medicine Company Profile

(Get Free Report)

Editas Medicine is a clinical-stage biotechnology company focused on translating the power of gene editing into a new class of transformative genomic medicines. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company leverages proprietary CRISPR/Cas9 and CRISPR/Cas12a (Cpf1) platforms to develop therapies aimed at correcting disease-causing genetic mutations. Editas Medicine’s research and development efforts span multiple therapeutic areas, including inherited retinal diseases, hemoglobinopathies, and oncology.

The company’s pipeline includes EDIT-101, a lead candidate designed to treat Leber congenital amaurosis type 10 (LCA10), which has entered early-stage clinical trials, and EDIT-301, targeting sickle cell disease and β-thalassemia using an ex vivo editing approach.

Featured Stories

Analyst Recommendations for Editas Medicine (NASDAQ:EDIT)

Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.